ArticleAIDS and behavior2025
Intimate Partner Violence and Determinants of HIV Seroconversion among Female Caregivers in Kwazulu-Natal, South Africa: Insights from the Asenze Longitudinal Study.
Article in AIDS and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Intimate partner violence (IPV) has been associated with HIV seroconversion vulnerability, but few studies have examined multiple IPV types and HIV status. This study investigates exposure to various IPV types and HIV seroconversion among female caregivers in KwaZulu-Natal (KZN), South Africa, using longitudinal data (2008-2021) from the Asenze cohort study. We compared IPV exposure at baseline (Wave 1[W1]), sociodemographic, and psychosocial characteristics between women living with HIV (WLHIV) vs. HIV-negative at baseline; HIV-negative at baseline who seroconverted by Wave 3 (W3) vs. remaining HIV-negative, using chi-squared and t-tests. We also assessed seroconversion over time in the cohort. At W1, of 580 participants (WLHIV = 139, HIV-negative = 431), 42% reported any IPV. Considering both current and other partners, WLHIV reported higher exposure to threatening IPV (34% vs. 23%, p = .005) and multiple IPV types (32% vs. 23%, p = .029). From an other partner, WLHIV reported more physical IPV (32% vs. 21%, p = .010), any IPV (35% vs. 26%, p = .049), and multiple IPV types (23% vs. 15%, p = .029). No significant differences in IPV from a current partner were found between WLHIV and HIV-negative women. Those who seroconverted by W3 vs. remained HIV-negative at W3 did not differ on any IPV exposures. Women who seroconverted were younger (28.2 vs. 37.8, p <.001) and more likely to report hazardous drinking at W1 (13% vs. 3%, p <.001). The high levels of HIV seroconversion and IPV indicate a persistent HIV and IPV epidemic among female caregivers in KZN, necessitating expanded research and interventions.
Indexed as
Identifiers
40327272What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.